Metastatic Breast Cancer Archives - Oncology Nurse Advisor

Metastatic Breast Cancer

Tucatinib Gets Priority Review for Locally Advanced or Metastatic HER2-Positive Breast Cancer

The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.

Next post in SABCS 2017